Derek DiRocco
Director/Board Member chez MINERALYS THERAPEUTICS, INC.
Fortune : 55 985 $ au 31/03/2024
Profil
Derek DiRocco is currently an Independent Director at Werewolf Therapeutics, Inc., a Director at Suzhou Connect Biopharma Co. Ltd., an Independent Non-Executive Director at Connect Biopharma Holdings Ltd., an Independent Director at 89bio, Inc., a Non-Executive Director at Achilles Therapeutics UK Ltd., an Independent Director at Acrivon Therapeutics, Inc., an Independent Director at Mineralys Therapeutics, Inc., a Director at 89Bio Ltd., a Partner at RA Capital Management LP, and a Partner at RA Capital Management LP (Private Equity).
In the past, Dr. DiRocco served as an Independent Director at iTeos Therapeutics, Inc. from 2020 to 2023, a Non-Executive Director at CANbridge Pharmaceuticals Inc. from 2020 to 2023, an Independent Director at Day One Biopharmaceuticals, Inc., an Independent Non-Executive Director at Achilles Therapeutics Plc from 2019 to 2022, and a Director at Canbridge Pharmaceuticals, Inc. (United States).
Dr. DiRocco completed his undergraduate degree at the College of the Holy Cross (Massachusetts) in 2002 and obtained a doctorate degree from the University of Washington in 2009.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 24/04/2023 | 7 830 ( 0,03% ) | 55 985 $ | 31/03/2024 | |
ITEOS THERAPEUTICS, INC.
-.--% | 13/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
89BIO INC
-.--% | 04/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
| 21/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Derek DiRocco
| Sociétés | Poste | Début |
|---|---|---|
| 89BIO, INC. | Director/Board Member | 01/04/2018 |
| WEREWOLF THERAPEUTICS, INC. | Director/Board Member | 01/12/2020 |
| ACRIVON THERAPEUTICS, INC. | Director/Board Member | 01/11/2021 |
| MINERALYS THERAPEUTICS, INC. | Director/Board Member | 08/06/2022 |
RA Capital Management LP
 RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Analyst-Equity | - |
89Bio Ltd.
 89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The private company is based in Herzliya, Israel. | Director/Board Member | - |
RA Capital Management LP (Private Equity)
 RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Private Equity Investor | 01/12/2017 |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Director/Board Member | - |
Suzhou Connect Biopharma Co. Ltd.
 Suzhou Connect Biopharma Co. Ltd. Pharmaceuticals: MajorHealth Technology Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China. | Director/Board Member | - |
Anciens postes connus de Derek DiRocco
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ ░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░ ░░░ ░░░░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Formation de Derek DiRocco
| University of Washington | Doctorate Degree |
| College of the Holy Cross (Massachusetts) | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 9 |
|---|---|
| 89BIO, INC. | Health Technology |
| WEREWOLF THERAPEUTICS, INC. | Health Technology |
| ITEOS THERAPEUTICS, INC. | Health Technology |
| ACRIVON THERAPEUTICS, INC. | Health Technology |
| DAY ONE BIOPHARMACEUTICALS, INC. | Health Technology |
| CONNECT BIOPHARMA HOLDINGS LIMITED | Health Technology |
| ACHILLES THERAPEUTICS PLC | Health Technology |
| MINERALYS THERAPEUTICS, INC. | Health Technology |
| CANBRIDGE PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
RA Capital Management LP
RA Capital Management LP Investment ManagersFinance RA Capital Management LP (RA Capital) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Peter Kolchinsky in 2004. RA Capital provides discretionary investment advisory services to Healthcare Funds and the Nexus Funds which are open only to certain financially sophisticated and high net-worth individuals and entities. | Finance |
Achilles Therapeutics UK Ltd.
Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom. | Health Technology |
Suzhou Connect Biopharma Co. Ltd.
Suzhou Connect Biopharma Co. Ltd. Pharmaceuticals: MajorHealth Technology Suzhou Connect Biopharma Co. Ltd. develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products include CBP-307, CBP-174, and CBP-201. The company was founded by Zheng Wei and William Pan in 2012 and is headquartered in Taicang, China. | Health Technology |
89Bio Ltd.
89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The private company is based in Herzliya, Israel. | Health Technology |
RA Capital Management LP (Private Equity)
RA Capital Management LP (Private Equity) Investment ManagersFinance RA Capital Management LP (Private Equity) (RA Capital) is a private equity & venture capital subsidiary of RA Capital Management LP founded by Peter Kolchinsky in 2004. The firm is headquartered in Boston, MA. | Finance |
Canbridge Pharmaceuticals, Inc. (United States)
 Canbridge Pharmaceuticals, Inc. (United States) BiotechnologyHealth Technology Part of CANbridge Pharmaceuticals Inc., Canbridge Pharmaceuticals is a rare disease-focused biopharmaceutical company based in Cambridge, MA. Canbridge Pharmaceuticals, Inc. (United States) was established in 2012 and is committed to researching, developing, and commercializing transformative therapies for rare diseases. | Health Technology |
